Key Highlights

Risk & Performance

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Phase 2

3(75.0%)

N/A

1(25.0%)

4Total

Phase 2(3)

N/A(1)

Loading network data...

Showing 5 of 5 trials

Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients

Role: collaborator

Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy

Role: collaborator

Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults

Role: collaborator

HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs

Role: collaborator

Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients

Role: collaborator

All 5 trials loaded